Increased receptor activator of nuclear factor kappa B ligand expressed on B10 cells in rheumatoid arthritis.
- Author:
Hong Jiang LIU
1
;
Xiao Feng GUO
1
;
Fan Lei HU
2
;
Cui Ping YAN
1
;
Xiang Jun CUI
1
;
Xue Liang YAN
1
;
Zhan Guo LI
2
;
Yuan JIA
2
;
Shu Lin SONG
1
Author Information
1. Department of Rheumatology and Immunology,the People's Hospital of China Three Gorges University,Yichang 443000, Hubei, China.
2. Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Antirheumatic Agents;
Arthritis, Rheumatoid/metabolism*;
Autoantibodies/metabolism*;
B-Lymphocytes, Regulatory/metabolism*;
Humans;
RANK Ligand/metabolism*;
Rheumatoid Factor
- From:
Journal of Peking University(Health Sciences)
2018;50(6):968-974
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To detect receptor activator of nuclear factor kappa B ligand (RANKL) expressed on B10 cells in rheumatoid arthritis (RA) and to evaluate the correlation between RANKL-producing B10 cells in RA and clinical features and laboratory parameters, trying to reveal the possible role of B10 cells in the pathogenesis of RA and the potential mechanism of impaired immunosuppressive capacities.
METHODS:25 RA patients and 20 healthy volunteers were enrolled. These RA patients did not received treatment with glucocorticoids, disease-modifying anti-rheumatic drug and biologics during the recent half of a year. The levels of RANKL-producing B10 cells were measured by flow cytometry (FCM) and polymerase chain reaction (PCR). The correlation between the frequencies of RANKL-producing B10 cells in RA and clinical data, laboratory parameters were analyzed. The role of tumor necrosis factor α (TNF-α) and interleukin 1β (IL-1β) in inducing RANKL expression in B10 cells was evaluated by in vitro stimulation assay. Independent samples t test, Pearson and Spearman correlation were used for statistical analysis.
RESULTS:B10 cells were capable of producing RANKL at a low level in health controls. The frequencies of RANKL-producing B10 cells were markedly higher in RA patients than in health controls (3.65%±1.59% vs. 2.25%±0.68%, P<0.01). The frequencies of these cells correlated positively with RA tender joint counts, swollen joint counts and disease activity score in 28 joints (DAS28) (r=0.479, P=0.035; r=0.519, P=0.008; r=0.526, P=0.019). However, no correlation was found between these cells and RA patient age, disease duration, or the levels of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA). After in vitro stimulation by TNF-α, but not IL-1β, B10 cells isolated from healthy donors demonstrated fundamentally upregulated expression of RANKL.
CONCLUSION:Our studies showed the frequencies of RANKL-producing B10 cells were markedly higher in RA patients, and their frequencies were positively correlated with RA tender joint counts, swollen joint counts and DAS28. These findings suggested that B10 cells might be involved in RA bone destruction.
